Metabolic Syndrome Before and After Initiation of Antiretroviral Therapy in Treatment-Naive HIV-Infected Individuals by Krishnan, Supriya et al.
Metabolic syndrome before and after initiation of antiretroviral
therapy in treatment-naïve HIV-infected individuals
S Krishnan, DSc1, JT Schouten, MD2, B Atkinson, MS3, T Brown, MD, PhD4, D Wohl, MD5,
GA McComsey, MD6, MJ Glesby, MD, PhD7, C Shikuma, MD8, R Haubrich, MD9, P Tebas,
MD10, TB Campbell, MD11, and DL Jacobson, PhD, MPH1
1Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA, US
2Department of Surgery, University of Washington School of Medicine, Seattle, WA, US
3Harborview Medical Center, Seattle, WA, US
4Division of Endocrinology and Metabolism, Johns Hopkins University, Baltimore, MD, US
5AIDS Clinical Trials Unit, University of North Carolina, Chapel Hill, NC, US
6Division of Pediatric Infectious Diseases and Rheumatology, Case School of Medicine,
Cleveland, OH, US
7Division of Infectious Diseases, Department of Medicine, Weill Cornell Medical Center, New
York, NY, US
8Hawaii Center for AIDS, University of Hawaii, Honolulu, Hawaii, US
9University of California San Diego, San Diego, CA, US
10Division of Infectious Diseases, University of Pennsylvania, Philadelphia, PA, US
11Division of Infectious Diseases, Department of Medicine, University of Colorado Denver,
Aurora, CO, US
Abstract
Background—Metabolic syndrome (MetS) is a cluster of risk factors for cardiovascular disease
and diabetes, many of which are associated with HIV and antiretroviral therapy (ART). We
examined prevalence and incidence of MetS, and risk factors for MetS in ART-naïve HIV-
infected individuals starting ART.
Methods—MetS, defined by the Adult Treatment Panel III criteria, was assessed at and after
ART initiation in HIV-infected individuals who enrolled in selected AIDS Clinical Trials Group
(ACTG) trials and were followed long-term after these trials as part of the ACTG Longitudinal
Linked Randomized Trials cohort. Cox proportional hazards models were used to examine risk
factors of incident MetS. Adjusted hazard ratios (aHR) and 95% confidence intervals (CI) are
reported.
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Results—At ART initiation, the prevalence of MetS was 20%. After ART initiation, the
incidence of MetS was 8.5 per 100 person-years. After adjusting for demographics and body mass
index, the risk of MetS was decreased for CD4+ T-cell counts>50 cells/mm3 (aHR = 0.62, 95%
CI=0.43 to 0.90 for CD4>500), and the risk was increased for HIV-1 RNA >400 copies/mL
(aHR=1.55 (95% CI=1.25 to 1.92) and use of a protease-inhibitor (PI) based regimen (relative to
no PI use, aHR=1.25 (95% CI=1.04 to 1.51) for any PI use).
Conclusion—In HIV-infected individuals on ART, virologic suppression and maintenance of
high CD4+ T-cell counts may be potentially modifiable factors that can reduce the risk of MetS.
The effect of MetS on the risk of cardiovascular disease and diabetes needs to be evaluated.
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Introduction
The continuing success of potent antiretroviral therapy (ART) has resulted in dramatic
reductions in HIV-associated morbidity and mortality. HIV-infected individuals are now
living longer. This longer life span has exposed them to the effects of aging, and other host
and environmental factors known to increase the risk of obesity, diabetes and cardiovascular
disease (CVD) in the general population (1). The HIV virus itself can cause lipid
abnormalities including high triglycerides and low HDL cholesterol (22), and the side
effects of antiretroviral medications have also been associated with metabolic and body
shape changes (2).
Metabolic syndrome (MetS) is an aggregation of central obesity and metabolic abnormalities
that confers an increased risk of CVD and type 2 diabetes (3). Since its introduction, the
definition of MetS has been under scrutiny especially since it excludes known CVD risk
factors such as smoking. The existence of MetS as a diagnostic entity is also controversial,
and there is limited data in HIV-infected populations.
The age-adjusted prevalence of MetS in the adult U.S. population is 34.3% (4); in HIV-
infected populations, the estimated prevalence ranges from 7–45% (5). Data on the
incidence of MetS in HIV-infected individuals receiving potent ART is limited by the cross-
sectional nature of most of the studies. A US-based HIV-infected cohort that included both
treatment experienced and naïve individuals reported an incidence of 1.2 per 100 person-
months (6), and an international study of HIV-infected adults initiating ART reported an
incidence of 12 per 100 person-years (7). Most of the existing data on factors associated
with MetS are from cross-sectional studies (5); few studies have examined factors associated
with MetS among ARV-naïve individuals after starting potent ART.
We examined the prevalence of MetS and factors associated with MetS in a large US-based
cohort of HIV-infected ART-naïve individuals at the time they started their ART regimens.
Further we determined the incidence of newly-developed MetS in this ART-naïve
population after they had started their ART regimens through randomized clinical trials. We
also examined the association of demographics, clinical factors, and ART use on the
prevalence and incidence of MetS.
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The AIDS Clinical Trials Group (ACTG) Longitudinal Linked Randomized Trials (ALLRT)
is a prospective cohort of HIV-infected participants (age ≥13 years) randomized to receive
ART regimens, immune-based therapies or treatment strategies in selected ACTG clinical
trials (8). ACTG sites that enrolled participants to ALLRT received approval by their
designated institutional review boards to conduct this study, and all ALLRT participants
provided written informed consent.
The present analysis included 2,554 ART-naïve individuals who enrolled in ALLRT from 3
parent trials (A5095, A5142 and A5202; enrollment period 2001–2007) (9–11). The ART
regimens used in these trials included either 1) three nucleoside reverse transcriptase
inhibitors (NRTIs), 2) two/three NRTIs with a non-nucleoside reverse transcriptase inhibitor
(NNRTI) or a boosted- protease inhibitor (PI), or 3) an NNRTI with a boosted PI.
The “baseline” visit was the parent trial entry visit (prior to the start of ART). When
individuals were enrolled in the parent trial, visits were scheduled according to the parent
trial protocol. When the parent study ended, data collection continued according to the
ALLRT protocol. Data were recorded by the study site staff using standard ACTG forms.
Definition of metabolic syndrome (MetS)
Since its introduction in 1998, various diagnostic criteria for MetS have been proposed (12);
The more widely used definitions for MetS are from International Diabetes Federation (IDF)
and the American Heart Association/National Heart, Lung, and Blood Institute (AHA/
NHLBI). In HIV-infected patients, there was 85% agreement in patient classification based
on these two definitions (33). More recently, the IDF and AHA/NHLBI agreed upon a
common definition, which was used in our study (12).
Based on the Adult Treatment Panel III (ATPIII) criteria (12), MetS was defined as the
presence of three or more of the following components: 1) waist circumference >88 cm in
women or >102 cm in men; 2) blood pressure ≥130 mm Hg systolic or ≥85 mm Hg diastolic
or use of antihypertensive medications; 3) triglycerides ≥150 mg/dL or use of lipid lowering
medications (niacin, fenofibrate, and gemfibrozil); 4) fasting blood glucose ≥100 mg/dL,
physician diagnosed diabetes or use of diabetic medications; 5) high density lipoprotein
cholesterol (HDL) <50 mg/dL in women or <40 mg/dL in men.
According to the ALLRT protocol, blood pressure readings, fasting lipid panel and glucose
were assessed every 16 weeks, and waist circumference was measured every 48 weeks. For
800 individuals, the first available waist circumference measurement was within 16 weeks
after baseline due to the timing of their ALLRT entry visit; for these individuals, the waist
circumference at week 16 was considered as baseline.
At baseline, there were 307 (12%) of 2,554 individuals with missing data on one or more of
the MetS components, and who could not be classified as having or not having MetS; these
307 individuals were excluded from the study population. Among the remaining 2,247
individuals, 450 individuals with three or more components at baseline were defined as
prevalent cases of MetS (even if they were missing data on other components). Those
without MetS at baseline were categorized as one of the following: 1) those with two
components and no missing data; 2) those with one component and missing data on ≤1
component, and; 3) those with no components and missing data on ≤2 components.
Similarly, incident cases were assessed during follow-up among the 1,797 individuals
without MetS at baseline.
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Prevalence of MetS at baseline (at ART initiation) was calculated as the number of cases at
baseline divided by the total analyzed population. Binary regression (log-binomial) was used
to evaluate associations between covariates and MetS at ART initiation. Baseline covariates
examined included age (years), sex, race/ethnicity, years of education, history of cigarette
smoking, body mass index (BMI, kg/m2), history of intravenous (IV) drug use, family
history of CVD, HIV-1 RNA viral load (copies/mL), and CD4+ T-cell count (cells/mm3).
Incidence of MetS was evaluated among those who did not have MetS at baseline. Person-
years at risk were calculated from baseline until first MetS diagnosis, death, end of follow-
up or June 30, 2009 (whichever came first). The incidence rate (IR) of MetS was calculated
as the number of incident cases divided by the total person-years at risk. Exact 95%
confidence intervals (CI) were calculated under a Poisson distribution. Cox proportional
hazards models and extended Cox models for time-dependent covariates were used to
calculate unadjusted (HR) and adjusted (aHR) hazard ratios and 95% CI. Baseline covariates
examined included all those stated above. Time-varying covariates (updated every 48
weeks) included CD4+ T-cell count, HIV-1 RNA viral load and ART use. Specifically, we
examined time-updated class of ART use (for example PI-containing regimen versus
regimen without PI) and time-updated use of specific antiretroviral medications.
Each subject’s follow-up time from baseline was divided into 48-week intervals. We
examined the association between ART use (any current ART use during the 48 week period
versus none), CD4+ T-cell count and HIV-1 RNA viral load for a 48-week interval, and risk
of MetS in the next interval. The “last value carried forward” method was used for missing
CD4+ T-cell and HIV-1 RNA viral load values.
For both prevalence and incidence analyses, univariate models were used to examine the
unadjusted associations between covariates and MetS. All covariates with a p-value ≤0.1
were added to the multivariable model. For the final multivariable model, age, sex, and race/
ethnicity were included regardless of p-value. For all other variables, only those that were
statistically significant (p<0.05) were retained in the final multivariable model.
We determined the frequency of each combination of metabolic abnormalities for all
prevalent and incident cases of MetS. For the incident cases, we examined the status of all
MetS components at baseline to see if the metabolic abnormality was already present at
baseline or developed during follow-up.
All analyses were performed using SAS version 9.2 (SAS Institute Inc, Cary, NC).
Results
Of the 3761 participants who enrolled in the three parent studies, 2554 had enrolled in
ALLRT. As stated in the Methods section, 307 of the 2554 individuals were excluded
because there was not enough information to classify their MetS status at baseline. There
were no significant differences in most demographic and clinical characteristics between the
final study population (N=2247) and the excluded individuals (N=307); the mean (SD)
fasting triglyceride level was higher in the excluded group than the final study population
(221 (226) versus 138 (117), p <.0001).
Prevalence of MetS at ART initiation
At baseline, 450 (20%) of the 2247 individuals had MetS. Table 1 shows the baseline
characteristics of the study population by baseline MetS status. At baseline, 88% of those
with MetS and 76% of those without MetS were greater than 30 years of age. Among those
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with MetS, 47% were white, 27% were black and 24% were Hispanic; among those without
MetS, 42% were white, 35% were black and 20% were Hispanic. In the multivariable model
shown in Table 2, older age and high BMI were significantly associated with an increased
prevalence of MetS, and black race was associated with a decreased prevalence of MetS at
baseline. Baseline CD4+ T-cell count, HIV-1 RNA viral load and other factors listed in
Table 1 were not associated with MetS at baseline, and were not included in the final model
presented in Table 2.
Incident MetS during follow-up after ART initiation
There were 478 incident cases of MetS among the 1,797 individuals (5,617 person-years of
follow-up) who were MetS-free at baseline. The estimated IR of MetS was 8.5 per 100
person-years (95% CI= 7.8 to 9.3). Table 3 presents the unadjusted IRs for covariates of
interest.
The factors that were independently associated with the incidence of MetS are presented in a
multivariable model in Table 4. Age at study entry, race/ethnicity, baseline BMI, time-
updated CD4+ T-cell count, time-updated HIV-1 RNA viral load, and time-updated use of a
PI-based regimen during follow-up were significantly associated with incident MetS. The
adjusted HR increased with increasing age and also with increasing BMI. Relative to a
CD4+ T-cell count of ≤50 cells/mm3, the adjusted HR decreased from 0.68 (95% CI= 0.48
to 0.96) for a CD4+ T-cell count of 51–200 to 0.62 (95% CI= 0.43 to 0.90) for a CD4+ T-
cell count of >500. The adjusted HR was 1.55 (95% CI= 1.25 to 1.92) for an HIV-1 RNA
viral load ≤400 copies/ml compared to >400 copies/ml. Finally, use of a PI-based regimen
was associated with an increased risk of MetS. We examined the prevalence of individual
MetS components by PI use: 26% of the 48-week time intervals when individuals were on a
PI-based regimen had elevated triglycerides, and 18% of the 48-week time intervals when
individuals were on a non-PI based regimen had elevated triglycerides; none of the other
MetS components had notable differences by PI-based regimen use. When we stratified by
time period (enrollment before and after 2005), the HRs for PI use were similar, but no
longer statistically significant. Education, family history of CVD and history of cigarette
smoking were not associated with MetS in the multivariable model.
We also examined time-updated use of specific PIs. Among 5617 person-years of follow-up,
62% were from a non-PI based regimen, 20% were from a lopinavir/ritonavir-containing
regimen, 16% were from an atazanavir/ritonavir-containing regimen, and the rest were from
other PI-containing regimens. In a model that adjusted for age, race/ethnicity, baseline BMI,
time-updated CD4 and time-updated HIV-1 RNA and excluded time on atazanavir/ritonavir
regimens, the HR for a time-updated lopinavir/ritonavir-containing regimen was 1.28 (95%
CI= 1.00 to 1.64, p-value=0.05) relative to a regimen without any PIs. The HR was 1.12
(95% CI= 1.00 to 1.25, p-value=0.04) for a time-updated atazanavir/ritonavir-containing
regimen relative to a regimen without PI (model adjusted for same covariates as above and
excluded time on lopinavir/ritonavir regimens). The use of an NRTI-based regimen (overall
NRTI use, stavudine use, abacavir use, tenofovir use) or a NNRTI-based regimen was not
significantly associated (p>0.05) with incident MetS.
Distribution of MetS components among prevalent and incident cases
The combination of high blood pressure, high triglycerides and low HDL was found among
40% of the prevalent and 49% of the incident cases. Figure 1 presents the distribution of
factors defining MetS among the 478 incident cases at baseline and at MetS incidence. The
figure shows that among the incident cases with low HDL as one of the components of
incident MetS, 59% had low HDL at baseline. In contrast, among the incident cases with
high triglycerides as one of the components of incident MetS, 58% developed
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hypertriglyceridemia during follow-up. Fifty-seven percent of the cases with high blood
pressure as one of the components of incident MetS had developed the high blood pressure
during follow-up.
Discussion
In this large cohort of HIV-infected ART-naïve individuals followed for a median of 2.8
years after ART initiation (maximum follow-up was 8.3 years), the incidence of MetS was
8.5 per 100 person-years. The most common set of MetS components during follow-up
included high triglycerides, low HDL and high blood pressure. In addition to age, race/
ethnicity, and high BMI, low CD4+ T-cell counts, lack of virologic suppression, and use of a
PI-based antiretroviral regimen were independently associated with a higher risk of
developing MetS. To our knowledge this is one of the few studies to prospectively examine
factors associated with incident MetS in ART-naïve HIV-infected individuals after ART
initiation.
At ART initiation, 20% of the individuals had MetS; at the end of follow-up, the prevalence
of MetS in those who were MetS-free at ART initiation was 27%. A small study of 60 ARV-
naïve subjects (83% male) in Spain found that the prevalence of MetS increased from 17%
to 25% after 48 weeks of ART (13). In a larger international study of 881 ARV-naïve
subjects (79% male), the prevalence before ART initiation was 8.5% and incidence during
follow-up after ART initiation was 12 per 100 person-years (7). Other studies reporting on
MetS in HIV-infected populations have been predominantly cross-sectional or have included
subjects already taking antiretroviral medications (5, 6, 14, 15). Using our large cohort of
ART-naïve individuals, we were able to assess the prevalence of MetS before ART initiation
as well as the progression to MetS during follow-up after ART initiation. Although some
studies suggest an association between MetS and the risk of CVD and diabetes in the HIV-
infected population, the role of MetS as an independent predictor of risk for CVD is unclear
(7, 16). Whether the incidence of MetS in our cohort contributes to a subsequent increased
risk of CVD and diabetes in this population of ART-naïve individuals after ART initiation
needs to be examined. Majority of subjects in our study qualified for MetS based on
hypertension, hypertriglyceridemia and low HDL, compared to NHANES in which the
majority qualified due to hypertension, hyperglycemia and abdominal obesity (28). A
possible explanation for this difference is that hypertriglyceridemia and low HDL are
associated with HIV disease and ART, while in the general population these conditions are
probably the result of obesity and other lifestyle factors (exercise and alcohol consumption).
Data comparing HIV-infected and HIV-infected populations are needed to examine if MetS
confers similar CVD risk in both populations.
Previous reports on the association between CD4+ T-cell count and the risk of MetS are
conflicting. While some have found no association (15, 16), two cross-sectional studies
found that a higher CD4+ T-cell count is associated with a higher risk of MetS (14, 17). In
contrast, in a cross-sectional study of 293 subjects, a CD4+ T-cell count less than 100 cells/
mm3 was associated with a higher risk of MetS (18). Using prospective data from our study,
we were able to examine time-updated CD4+ T-cell levels in ART-naïve subjects after ART
initiation using a multivariable model that included demographic and other HIV-associated
factors. Relative to CD4+ T-cell counts of ≤50 cells/mm3, the risk of MetS was decreased
for each increasing level of CD4. The association of CD4+ T-cell count with MetS may be
explained by higher levels of inflammation and immune activation among those with more
advanced HIV disease. Data from the ALLRT cohort on inflammation and risk of diabetes
show that those who developed diabetes had lower CD4+ T- cell counts (19). Residual
immune activation/inflammation similar to that observed by Brown et al, may also explain
the association with time-updated CD4+ T-cell count even though there was a lack of
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association with baseline CD4 count. It is also possible that a higher CD4+ T-cell count is
reflective of better adherence to medications and a healthier lifestyle consisting of a good
diet and physical activity; and this then further reduces the risk of MetS. However, we did
not have data on diet and exercise to evaluate this hypothesis.
Consistent with previous reports (14, 18, 6, 20), HIV-1 RNA >400 copies/mL was
associated with a higher risk of incident MetS in our cohort. A possible explanation for this
finding is that HIV can cause lipid abnormalities including elevated triglycerides due to a
combination of hepatic very low-density lipoprotein overproduction and reduced triglyceride
clearance, and low HDL due to poor nutritional state and weight loss (21–23). Indeed, we
also found that high triglycerides and low HDL were the most common MetS components;
similar observations have been reported in other studies (5).
Specific ART regimens show associations with individual components of MetS. Proposed
mechanisms for PIs can induce insulin resistance by inhibiting the glucose transporter 4 and
by reducing peroxisomal proliferator-activated receptor activity, and NRTIs can cause
mitochondrial toxicity that leads to fat cell apoptosis, elevated free fatty acids and finally
insulin resistance and hypertriglyceridemia (24, 25). Evidence also suggests a link between
MetS and PIs, and specifically an increased risk for lopinavir/ritonavir (6, 26). For NRTIs,
studies suggest an increased risk of MetS for those on stavudine (15, 26), or didanosine (6).
In our study, we found an association between the use of a PI-based regimen and the risk of
MetS; however there was no association between NRTI use, NNRTI use and MetS risk. The
high prevalence of elevated triglycerides when subjects were on a PI-based regimen relative
to when they were not on a PI-based regimen suggests that the association between PI use
and MetS is probably mediated by high triglycerides. When we examined the use of specific
antiretroviral medications, none were significantly associated with MetS in the multivariate
model that included demographics, CD4+ T-cell count and HIV-1 RNA viral load. Since
enrollment in the parent studies began in 2001, some of the older regimens examined may
no longer be in use. A next step to understanding the role of ART in the development of
MetS would be to evaluate if newer ART drugs and regimens are associated with MetS.
Current treatment options for MetS include switching antiretroviral agents (24). Evidence
suggests that switching a PI to certain NRTIs or NNRTIs in virally suppressed patients does
not affect antiviral efficacy and may partly reverse metabolic changes (27). Whether such
switching of regimens decreases the incidence of MetS needs to be evaluated.
Similar to findings from other HIV-infected populations, the risk of MetS increased with
increasing age (17, 20, 26). The prevalence of MetS also varies by race/ethnicity, with lower
prevalence in non-Hispanic black men than non-Hispanic white men possibly due to lower
triglycerides, higher HDL, and lower waist circumferences in non-Hispanic black men (28,
29). In our study that was largely male (80% male), compared to those of white race, non-
Hispanic blacks had a lower risk of MetS. Obesity was independently associated with a
higher risk of developing MetS in our cohort; relative to those with a normal BMI at
baseline, the risk of MetS was almost four times higher in those who were obese. Prior
studies in the general population and in the HIV-infected population have also reported a
similar association between obesity and MetS (30). At entry, 31% and 8% of our cohort
were overweight and obese, respectively; similar prevalences were noted in the US military
cohort (31) that concluded that HIV-infected patients are increasingly overweight or obese
at HIV diagnosis and during the course of HIV infection.
Our study has some limitations. We had to exclude 307 individuals at baseline because of
missing data on MetS components; however, a comparison of demographics and clinical
characteristics showed that the excluded group was similar to the study population. We did
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not have data on alcohol use, exercise, or nutrition/caloric intake, all of which have been
shown to be associated with MetS in other studies (15, 17). Also, we did not have data on
use of supplements such as fish oil that can be used to lower triglycerides (32). And finally,
the regimens used in our study population only included a limited number of PIs; the
majority of PI-based regimens in our study consisted of either lopinavir/ritonavir or
atazanavir/ritonavir.
A primary strength of our study is the unique cohort of HIV-infected individuals who were
treatment naïve at entry, randomized to treatment regimens in clinical trials, and rigorously
monitored and followed long-term after completion of the original clinical trial. This
prospectively followed cohort had scheduled visits during their parent trial and during
follow-up in ALLRT which ensured that all components of MetS were collected using
standardized methods at regular intervals. This standardized data collection also made it
possible for us to examine a large array of demographic and clinical risk factors for MetS.
In conclusion, in our large cohort of HIV-infected ART-naïve persons, we found that apart
from the traditional factors such as age and BMI, HIV-associated factors such as low CD4+
T-cell count and lack of virologic suppression are associated with an increased risk of
developing MetS. In addition, use of a PI-based regimen was associated with an increased
risk of developing MetS. Our findings support the importance of achieving both virologic
suppression and immune restoration to avoid MetS. If indeed MetS increases the risk of
diabetes and CVD, reducing MetS in HIV-infected populations may be an important step in
reducing the burden of CVD and diabetes in this population.
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Table 1







Age (years) ≤30 57 (12) 437 (24)
31–40 144 (33) 717 (40)
41–50 166 (36) 484 (27)
>50 83 (19) 159 (9)
Sex male 330 (73) 1511 (84)
Race white non-Hispanic 212 (47) 753 (42)
black non-Hispanic 120 (27) 628 (35)
Hispanic 108 (24) 357 (20)
other 10 (2) 55 (3)
Education (years) <12 87 (19) 294 (16)
12 106 (23) 392 (22)
13–15 159 (35) 644 (36)
≥16 98 (22) 467 (26)
Family History of CVD yes 109 (24) 310 (17)
Smoking status ever smoker 265 (59) 1053 (59)
Body mass index (kg/m2) <25 92 (21) 1103 (61)
25–29 163 (36) 551 (31)
≥30 194 (43) 137 (8)
IV drug use (current or previous) ever 40 (9) 168 (9)
CD4+ T-cell count (cells/mm3) ≤50 78 (17) 354 (20)
51–200 112 (25) 464 (26)
201–350 147 (33) 603 (33)
351–500 74 (16) 251 (14)
>500 39 (9) 123 (7)
HIV-1 RNA (copies/mL) <10,000 55 (12) 199 (11)
10–100,000 259 (58) 1050 (58)
>100,000 136 (29) 548 (31)
Randomized ART regimen* 2NRTI+1NNRTI 192 (43) 725 (40)
PI+1NNRTI 29 (7) 141 (8)
PI+2NRTI 150 (34) 574 (32)
3NRTI 47 (11) 183 (10)
3NRTI+1NNRTI 31 (7) 172 (11)
Waist circumference (cm)** mean (SD) 101 (14) 86 (10)
Blood pressure diastolic (mmHg) mean (SD) 82 (10) 74 (9)
Blood pressure systolic (mmHg) mean (SD) 129 (15) 117 (13)
Fasting blood glucose (mg/dl) mean (SD) 99 (34) 83 (13)
Fasting triglycerides (mg/dl) mean (SD) 218 (195) 119 (75)
Fasting HDL cholesterol (mg/dl) mean (SD) 33 (16) 38 (13)
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Data are number (%) unless otherwise indicated. MetS, metabolic syndrome; ART, antiretroviral therapy; CVD, cardiovascular disease; NRTI,
nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
*
PI use at baseline was either lopinavir/ritonavir (37%) or atazanavir/ritonavir (63%) of total PI use. NNRTI used was Efavirenz. Among those
who started a regimen with NRTI, 74% were on lamivudine (3TC) and 26% on emtricitabine (FTC); additional NRTIs used included tenofivir
(32%), abacavir (27%), abacavir+zidovudine (21%), zidovudine (16%) and stavudine (4%).
**
All values measured at entry except waist circumference; waist circumference was measured either at entry or within 16 weeks based on the
protocol design.
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Table 2
Factors associated with MetS at ART initiation in ART-naïve HIV-infected individuals. (N=2247)
Unadjusted Adjusted*
RR (95% CI) p-value RR (95% CI) p-value
Age at baseline (years)
  ≤30 ref - ref -
  31–40 1.45 (1.09, 1.93) 0.001 1.19 (0.92, 1.56) 0.2
  41–50 2.21 (1.68, 2.92) <.0001 1.65 (1.29, 2.12) <.0001
  >50 2.97 (2.20, 4.01) <.0001 1.99 (1.54, 2.56) <.0001
Sex
  male ref - ref -
  female 1.65 (1.38, 1.97) <.0001 1.09 (0.97, 1.23) 0.2
Race
  white non-Hispanic ref - ref -
  black non-Hispanic 0.73 (0.59, 0.89) 0.002 0.69 (0.58, 0.81) <.0001
  Hispanic and other 1.06 (0.86, 1.29) 0.59 1.00 (0.87, 1.16) 0.9
Baseline BMI (kg/m2)
  <25 ref - ref -
  25–29 2.95 (2.33, 3.74) <.0001 2.82 (2.22, 3.57) <.0001
  ≥30 7.57 (6.11, 9.39) <.0001 6.91 (5.55, 8.60) <.0001
MetS, metabolic syndrome; ART, antiretroviral therapy; RR, relative risk; CI, confidence interval; BMI, body mass index.
*
Model includes all covariates listed in the table. Baseline CD4+ T-cell count, baseline HIV-1 RNA viral load, years of education, IV drug use and
smoking status were not significant at 0.05 level.
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Table 3








  ≤30 76 1357 6.4 (4.4 to 7.0)
  31–40 195 2264 8.6 (7.4 to 9.9)
  41–50 150 1510 9.9 (8.4 to 11.7)
  >50 57 486 11.7 (8.8 to 15.2)
Sex
  male 394 4664 8.5 (7.6 to 9.3)
  female 84 954 8.8 (7.0 to 10.9)
Race
  White non-Hispanic 236 2304 10.2 (8.9 to 11.6)
  black non-Hispanic 131 2074 6.3 (5.3 to 7.5)
  Hispanic 104 1048 10.0 (8.1 to 12.0)
  other 7 178 3.9 (1.6 to 8.1)
Education (years)
  <12 75 939 7.9 (6.3 to 10.0)
  12 104 1193 8.7 (7.1 to 10.6)
  13–15 172 2010 8.5 (7.3 to 9.9)
  ≥16 127 1475 8.6 (7.2 to 10.2)
Family History of CVD
  no 382 4666 8.1 (7.4 to 9.0)
  yes 96 951 10.1 (8.2 to 12.3)
Body mass index (kg/m2)
  <25 215 3605 5.9 (5.2 to 6.8)
  25–29 194 1666 11.6 (10.0 to 13.4)
  ≥30 68 334 20.3 (15.8 to 25.8)
Smoking status
  never smoker 203 2416 8.3 (7.2 to 9.5)
  ever smoker 275 3199 8.7 (7.7 to 9.7)
Time updated characteristics
CD4+ T-cell count (cells/mm3)
  ≤50 56 363 15.4 (11.6 to 20.0)
  51–200 81 810 10.0 (7.9 to 12.4)
  201–350 131 1478 8.8 (7.4 to 10.5)
  351–500 82 1286 6.4 (5.1 to 7.9)
  >500 128 1732 6.5 (6.1 to 8.8)
HIV-1 RNA (copies/mL)
  ≤400 231 3547 6.5 (5.7 to 7.4)
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Number of
cases
Person-years IR per 100 person-years
(95% CI)
  >400 247 2124 7.3 (10.2 to 13.1)
NRTI use
  no 43 505 8.5 (6.2 to 11.5)
  yes 435 5166 8.4 (7.6 to 9.2)
NNRTI use
  no 207 2391 8.6 (7.5 to 9.9)
  yes 271 3280 8.3 (7.3 to 9.3)
PI use
  no 273 3531 7.7 (6.8 to 8.7)
  yes 205 2140 9.6 (8.3 to 10.9)
Lopinavir/ritonavir use
  no 393 4763 8.2 (7.4 to 9.1)
  yes 85 908 9.4 (7.5 to 11.6)
Atazanavir/ritonavir use
  no 365 4497 8.1 (7.3, 8.9)
  yes 113 1174 9.6 (7.9, 11.5)
Stavudine use
  no 444 5338 8.3 (7.6 to 9.1)
  yes 34 333 10.2 (7.1 to 14.3)
MetS, metabolic syndrome; ART, antiretroviral therapy; IR, incidence rate; CI, confidence interval; CVD, cardiovascular disease; NRTI,
nucleoside reverse transcriptase inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease inhibitor.
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Table 4








  ≤30 ref - ref -
  31–40 1.54 (1.18, 2.01) 0.001 1.33 (1.02, 1.74) 0.04
  41–50 1.76 (1.34, 2.32) <.0001 1.47 (1.11, 1.94) 0.01
  >50 2.03 (1.44, 2.87) <.0001 1.91 (1.35, 2.69) 0.0003
Sex
  male ref - ref -
  female 1.06 (0.84, 1.34) 0.6 1.00 (0.78, 1.28) 0.9
Race
  white non-Hispanic ref - ref -
  black non-Hispanic 0.62 (0.50, 0.77) <.0001 0.53 (0.43, 0.67) <.0001
  Hispanic 0.96 (0.76, 1.21) 0.4 0.89 (0.70, 1.13) 0.3
  other 0.39 (0.19, 0.83) 0.02 0.43 (0.20, 0.92) 0.03
BMI (kg/m2)
  <25 Ref - ref -
  25–29 1.92 (1.58, 2.33) <0.0001 2.00 (1.64, 2.43) <.0001
  ≥30 3.19 (2.43, 4.19) <0.0001 3.63 (2.71, 4.83) <.0001
Time-updated CD4 (cells/mm3)
  ≤50 ref - ref
  51–200 0.65 (0.46, 0.92) 0.01 0.68 (0.48, 0.96) 0.03
  201–350 0.58 (0.42, 0.79) 0.001 0.64 (0.46, 0.90) 0.01
  351–500 0.42 (0.30, 0.58) <.0001 0.50 (0.34, 0.72) 0.0002
  >500 0.48 (0.35, 0.66) <.0001 0.62 (0.43, 0.90) 0.01
Time-updated HIV-1 RNA (copies/mL)
  ≤400 ref - ref -
  >400 1.79 (1.49, 2.14) <.0001 1.55 (1.25, 1.92) <.0001
Time-updated PI use
  no ref ref -
  yes 1.24 (1.03, 1.48) 0.02 1.25 (1.04, 1.51) 0.01
*
model includes all covariates listed in the table.
Note: MetS, metabolic syndrome; ART, antiretroviral therapy; HR, hazard ratio; CI, confidence interval; BMI, body mass index; PI, protease
inhibitor.
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